secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-05-21T23:59:59+00:00
Accession:  0001104659-24-063829
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio publishes Posiphen PK comparison across species in Biomolecules
---------------------------------------------------------------------------

- Publication in Biomolecules compares Posiphen pharmacokinetics across mouse, rat, dog, and human samples.
- Posiphen reaches peak plasma concentration quickly, with high brain and CSF absorption.
- Drug metabolizes into N1-norposiphen and N8-norposiphen; rapid clearance in plasma but longer retention in brain/CSF.
- Absorption, distribution, metabolism, and excretion similar in healthy volunteers and Alzheimer's/Parkinson's patients.
- CEO Maria Maccecchini states publication consolidates years of research for a holistic view of Posiphen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924063829/0001104659-24-063829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924063829/tm2415055d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-063829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer